Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

The presence of activating somatic mutations in codons 542 and 545 of exon 9 (p.E542K c.1624G>A and p.E545K c.1633G>A) and in codon 1047 of exon 20 (p.H1047R c.3140A>G and p.H1047L c.3140A>T) of PIK3CA gene encoding catalytic p110α-subunit of phosphatidylinositol-3-kinase was studied in tumors of 473 breast cancer patients by multiplex allele-specific real-time PCR. Fifty-eight (12.3%) different mutations were found. An increase in the frequency of PIK3CA gene mutations with disease progression (from 2.4 to 28.7% with tumor progression from I-IIa to III-IV stage; p=0.0001) and a trend towards its increase in the tumors with unfavorable prognostic characteristics (high histological grade, triple negative phenotype) were demonstrated. The presence of the studied PIK3CA gene mutations in tumors significantly reduces relapse-free survival in the total group and in stage III cancer patients.

Об авторах

M. Filipenko

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Автор, ответственный за переписку.
Email: biochimia@yandex.ru
Россия, Novosibirsk; Novosibirsk

N. Os’kina

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences

Email: biochimia@yandex.ru
Россия, Novosibirsk

I. Oskorbin

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Email: biochimia@yandex.ru
Россия, Novosibirsk; Novosibirsk

O. Mishukova

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Email: biochimia@yandex.ru
Россия, Novosibirsk; Novosibirsk

L. Ovchinnikova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Россия, Moscow

E. Gershtein

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Россия, Moscow

N. Kushlinskii

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Россия, Moscow


© Springer Science+Business Media, LLC, 2017

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах